Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Get more Watchlists, Portfolios, Custom Views and Chart Templates with Barchart Plus. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:

Vaccitech Plc ADR (VACC)

Vaccitech Plc ADR (VACC)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Help
Go To:
Investigational Immunotherapy Treatments Offering Promise in Treating Pancreatic Cancer as Risk Factors Rise FinancialNewsMedia - Tue Sep 26, 2023

EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:VACC),(NASDAQ:BPTS),(NASDAQ:RNAZ),(NYSE:BMY) EQNX::TICKER_END

BMY : 58.64 (+0.70%)
ONCY : 0.9654 (-1.49%)
ONC.TO : 1.35 (-1.46%)
VACC : 5.00 (+11.36%)
BPTS : 8.22 (-15.28%)
RNAZ : 0.3800 (unch)
Investigational Immunotherapy Treatments Offering Promise in Treating Pancreatic Cancer as Risk Factors Rise PR Newswire - Tue Sep 26, 2023

/PRNewswire/ -- FinancialNewsMedia.com News Commentary - There has been a rise in the prevalence of cancer in the past several years. Overall, there is a rapid...

ONC.TO : 1.35 (-1.46%)
ONCY : 0.9654 (-1.49%)
VACC : 5.00 (+11.36%)
BPTS : 8.22 (-15.28%)
RNAZ : 0.3800 (unch)
BMY : 58.64 (+0.70%)
Pharmaron’s Liverpool UK Gene Therapy CDMO Commences Major Site Expansion Following UK Government Grant to Support £151m Investment Business Wire - Wed Mar 29, 2023

Pharmaron Beijing Co., Limited (Stock Code: 300759.SZ/3759.HK) (“Pharmaron”) announced today that their Liverpool, UK based Gene Therapy CDMO has received a prestigious grant from the UK Government’s...

VACC : 5.00 (+11.36%)
Canadian CPI, U.S. Home Sales Featured Next Week Baystreet - Fri Mar 17, 2023

Monday U.S. Featured Earnings PDD Holdings Inc. (NASDAQ:PDD) (Q4) Reported EPS of $1.00, ...

PDD : 98.60 (-5.27%)
FL : 23.33 (+3.92%)
RETA : 172.36 (+0.02%)
NKE : 76.92 (+2.42%)
TME : 11.40 (-1.04%)
ONON : 57.42 (+2.19%)
CTAS : 221.03 (-0.21%)
CHWY : 34.70 (-3.26%)
FUL : 75.82 (+1.27%)
ACN : 359.38 (-0.46%)
GIS : 64.63 (+0.80%)
DRI : 167.73 (+1.93%)
Vaccitech Reports Second Quarter 2022 Financial Results and Recent Corporate Developments Globe Newswire - Tue Aug 9, 2022

OXFORD, United Kingdom, Aug. 09, 2022 (GLOBE NEWSWIRE) -- Vaccitech plc (NASDAQ: VACC) today announced its financial results for the second quarter ended...

VACC : 5.00 (+11.36%)
Vaccitech to Present at the William Blair Biotech Focus Conference 2022 Globe Newswire - Thu Jul 7, 2022

OXFORD, United Kingdom, July 07, 2022 (GLOBE NEWSWIRE) -- Vaccitech plc (NASDAQ: VACC), a clinical-stage biopharmaceutical company engaged in the...

VACC : 5.00 (+11.36%)
Vaccitech’s VTP-300 induced sustained reductions of surface antigen in patients with chronic hepatitis B both as a monotherapy and in combination with a single low dose of anti-PD-1 Globe Newswire - Wed Jun 22, 2022

VTP-300 as a monotherapy and in combination with a single administration of low-dose nivolumab was administered, with no treatment-related serious adverse...

VACC : 5.00 (+11.36%)
Vaccitech to Present at the Jefferies Healthcare Conference Globe Newswire - Mon Jun 6, 2022

OXFORD, United Kingdom, June 06, 2022 (GLOBE NEWSWIRE) -- Vaccitech plc (NASDAQ: VACC), a clinical-stage biopharmaceutical company engaged in the...

VACC : 5.00 (+11.36%)
Arbutus and Vaccitech Dose First Patient in Phase 2a Clinical Trial Combining Therapies for the Treatment of Chronic Hepatitis B Virus Globe Newswire - Mon Jun 6, 2022

Trial will evaluate AB-729, an RNAi therapy in combination with VTP-300, an immunotherapeutic, and NA therapy WARMINSTER, Pa. and OXFORD, U.K., June 06,...

ABUS : 3.50 (+1.16%)
VACC : 5.00 (+11.36%)
Vaccitech to Present at the H.C. Wainwright Global Investment Conference Globe Newswire - Fri May 20, 2022

OXFORD, United Kingdom, May 20, 2022 (GLOBE NEWSWIRE) -- Vaccitech plc (NASDAQ: VACC), a clinical-stage biopharmaceutical company engaged in the...

VACC : 5.00 (+11.36%)
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar

[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot